These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 15261686)

  • 21. Intensive lipid lowering with atorvastatin in coronary disease.
    Modest GA
    N Engl J Med; 2005 Jul; 353(1):93-6; author reply 93-6. PubMed ID: 16003833
    [No Abstract]   [Full Text] [Related]  

  • 22. Statins in the prevention of transplant coronary artery disease: in pediatric heart recipients.
    Pahl E
    Pediatr Transplant; 2007 Aug; 11(5):459-60. PubMed ID: 17631010
    [No Abstract]   [Full Text] [Related]  

  • 23. One-year atorvastatin treatment in hypercholesterolemic patients with or without carotid artery disease.
    Avellone G; Di Garbo V; Abruzzese G; Campisi D; De Simone R; Raneli G; Licata G
    Int Angiol; 2006 Mar; 25(1):26-34. PubMed ID: 16520721
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Achievement of optimal combined lipid values in a managed care setting: is a new treatment paradigm needed?
    Sarawate CA; Cziraky MJ; Stanek EJ; Willey VJ; Corbelli JC; Charland SL
    Clin Ther; 2007 Jan; 29(1):196-209. PubMed ID: 17379061
    [TBL] [Abstract][Full Text] [Related]  

  • 25. LDL-Cholesterol is the King.
    Goumas GS
    Angiology; 2009; 60(3):387-8. PubMed ID: 19497926
    [No Abstract]   [Full Text] [Related]  

  • 26. [Optimal lipid lowering therapy for coronary heart diseases patients in secondary prevention: moderate or aggressive LDL decrease preferred?].
    MMW Fortschr Med; 2006 Nov; 148(48):54-5. PubMed ID: 17615773
    [No Abstract]   [Full Text] [Related]  

  • 27. [Obesity and cardiovascular morbidity].
    Berg A; Bönner G
    Dtsch Med Wochenschr; 2005 Apr; 130(14):893-7. PubMed ID: 15800824
    [No Abstract]   [Full Text] [Related]  

  • 28. [Aggressive statin therapy reduces the progression of atherosclerosis-- DMW15/2005].
    Taut V
    Dtsch Med Wochenschr; 2006 Mar; 131(9):460; author reply 460. PubMed ID: 16493575
    [No Abstract]   [Full Text] [Related]  

  • 29. The case for medical treatment in chronic stable coronary artery disease.
    Nash DT
    Arch Intern Med; 2005 Dec 12-26; 165(22):2587-9, discussion 2593-4. PubMed ID: 16344414
    [No Abstract]   [Full Text] [Related]  

  • 30. Optimal medical management of peripheral arterial disease.
    Rice TW; Lumsden AB
    Vasc Endovascular Surg; 2006; 40(4):312-27. PubMed ID: 16959725
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Achieving cholesterol goals. Current and future drug therapies.
    Jones PH
    Postgrad Med; 2003 Aug; 114(2 Suppl):14-21. PubMed ID: 19667635
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Reduction in estimated risk for coronary artery disease after use of ezetimibe with a statin.
    Sampalis JS; Bissonnette S; Habib R; Boukas S;
    Ann Pharmacother; 2007 Sep; 41(9):1345-51. PubMed ID: 17666579
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [New results in the management of hypercholesterolemia].
    Sármán B
    Orv Hetil; 2005 Sep; 146(39):1999-2004. PubMed ID: 16265867
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The role of treatment to increase HDL-cholesterol and decrease triglyceride concentrations in prevention of coronary heart disease in Type 2 diabetes.
    Wild S; Byrne CD
    Diabet Med; 2004 Sep; 21 Suppl 4():8-11. PubMed ID: 15315518
    [No Abstract]   [Full Text] [Related]  

  • 35. Predicting benefit from statins by C-reactive protein, LDL-cholesterol or absolute cardiovascular risk.
    Stewart RA
    Future Cardiol; 2009 May; 5(3):231-6. PubMed ID: 19656039
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A triumvirate of targets in the prevention and treatment paradigm for cardiovascular disease.
    Packard C
    Atheroscler Suppl; 2006 Apr; 7(1):21-9. PubMed ID: 16504600
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Extent to which accepted serum lipid goals are achieved in a contemporary general medical population with coronary heart disease risk equivalents.
    Alsheikh-Ali AA; Lin JL; Abourjaily P; Ahearn D; Kuvin JT; Karas RH
    Am J Cardiol; 2006 Nov; 98(9):1231-3. PubMed ID: 17056335
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cholesterol rethink for high-risk patients.
    Med Lett Drugs Ther; 2004 May; 46(1182):37-9. PubMed ID: 15136771
    [No Abstract]   [Full Text] [Related]  

  • 39. Statins targeting inflammation by lowering low-density lipoprotein?
    Tuzcu EM; Nicholls SJ
    J Am Coll Cardiol; 2007 May; 49(20):2010-2. PubMed ID: 17512356
    [No Abstract]   [Full Text] [Related]  

  • 40. The gravity of JUPITER (Justification for the Use of Statins in Primary Prevention: An Intervention Trial Evaluating Rosuvastatin).
    O'Keefe JH; Carter MD; Lavie CJ; Bell DS
    Postgrad Med; 2009 May; 121(3):113-8. PubMed ID: 19491548
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.